Blasting 'speculative commentary,' GSK offers update on Zantac litigation and vows to 'vigorously defend itself'
GSK wants to address “speculative commentary” about its Zantac litigation head on.
The pharma giant put out a lengthy statement after a suite of analysts sounded the alarm on the potential impact of the ongoing personal injury lawsuits, which triggered big plunges for its stock as well as that of its consumer health spinout, Haleon, and Sanofi, which also sold the drug at one point.
Zantac, a well-known drug used to reduce stomach acid production, was recalled globally back in 2019 over “unacceptable levels of N-nitrosodimethylamine,” a carcinogen also known as NDMA for short. The following year, the FDA and EMA recommended that all products containing the active ingredient ranitidine be withdrawn.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.